These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24353687)

  • 1. Effectiveness of sodium hyaluronate eye gel in patients with dry eye disease: a multi-centre, open label, uncontrolled study.
    Saeed N; Qazi Z; H Butt N; Siddiqi A; Maheshwary N; Athar Khan M
    Pak J Med Sci; 2013 Jul; 29(4):1055-8. PubMed ID: 24353687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium hyaluronate eye drops in the treatment of dry eye disease: an open label, uncontrolled, multi-centre trial.
    Cheema A; Aziz T; Mirza SA; Siddiqi A; Maheshwary N; Khan MA
    J Ayub Med Coll Abbottabad; 2012; 24(3-4):14-6. PubMed ID: 24669598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye.
    Kinoshita S; Oshiden K; Awamura S; Suzuki H; Nakamichi N; Yokoi N;
    Ophthalmology; 2013 Jun; 120(6):1158-65. PubMed ID: 23490326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Two-Week, Randomized, Double-masked Study to Evaluate Safety and Efficacy of Lubricin (150 μg/mL) Eye Drops Versus Sodium Hyaluronate (HA) 0.18% Eye Drops (Vismed®) in Patients with Moderate Dry Eye Disease.
    Lambiase A; Sullivan BD; Schmidt TA; Sullivan DA; Jay GD; Truitt ER; Bruscolini A; Sacchetti M; Mantelli F
    Ocul Surf; 2017 Jan; 15(1):77-87. PubMed ID: 27614318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, Safety, and Tolerability of a Novel Cyclosporine, a Formulation for Dry Eye Disease: A Multicenter Phase II Clinical Study.
    Peng WY; Chen RX; Dai H; Zhu L; Li Y; Gao ZQ; Li XY; Zhou SY
    Clin Ther; 2021 Mar; 43(3):613-628. PubMed ID: 33546885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tear function and abnormalities of ocular surface: relationship with subjective symptoms of dry eye in ibadan, Nigeria.
    Bekibele C; Baiyeroju A; Ajaiyeoba A; Akang E; Ajayi B
    Middle East Afr J Ophthalmol; 2008 Jan; 15(1):12-5. PubMed ID: 20379423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, tolerability and comfort of a 0.3% hypromellose gel ophthalmic lubricant in the treatment of patients with moderate to severe dry eye syndrome.
    Tauber J
    Curr Med Res Opin; 2007 Nov; 23(11):2629-36. PubMed ID: 17868503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal changes in dry eye symptoms and signs following lifitegrast therapy and relationship to tear osmolarity.
    Pepose JS; Qazi MA; Devries DK
    Clin Ophthalmol; 2019; 13():571-579. PubMed ID: 30992657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Nonpreserved Sodium Hyaluronate Artificial Tears in Dry Eye Disease Patients Treated with Prostaglandin Analogs for Primary Open-Angle Glaucoma: A Prospective, Nonrandomized, Open-Label Pilot Study.
    Coco G; Iannetta D; Febbraro I; Elmo E; Manni G
    J Ophthalmol; 2022; 2022():1320996. PubMed ID: 36505508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency and impact of individual symptoms on quality of life in dry eye disease in patients presenting to a tertiary care hospital.
    Arif SA; Khan MI; Abid MS; Babar A; Arif MA; Jahanzaib HM; Khan I
    J Pak Med Assoc; 2021 Apr; 71(4):1063-1068. PubMed ID: 34125744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study.
    Kinoshita S; Awamura S; Oshiden K; Nakamichi N; Suzuki H; Yokoi N;
    Ophthalmology; 2012 Dec; 119(12):2471-8. PubMed ID: 23009892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, open-label, 52-week study of 2% rebamipide (OPC-12759) ophthalmic suspension in patients with dry eye.
    Kinoshita S; Awamura S; Nakamichi N; Suzuki H; Oshiden K; Yokoi N;
    Am J Ophthalmol; 2014 Mar; 157(3):576-83.e1. PubMed ID: 24246575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
    Holland EJ; Luchs J; Karpecki PM; Nichols KK; Jackson MA; Sall K; Tauber J; Roy M; Raychaudhuri A; Shojaei A
    Ophthalmology; 2017 Jan; 124(1):53-60. PubMed ID: 28079022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.
    Chen M; Gong L; Sun X; Xie H; Zhang Y; Zou L; Qu J; Li Y; He J
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):361-6. PubMed ID: 20698799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study to assess the clinical use of Fluorescein Meniscus Time (FMT) with Tear Break up Time (TBUT) and Schirmer's tests (ST) in the diagnosis of dry eyes.
    Kallarackal GU; Ansari EA; Amos N; Martin JC; Lane C; Camilleri JP
    Eye (Lond); 2002 Sep; 16(5):594-600. PubMed ID: 12194075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized controlled trial of trehalose: An efficient autophagic bioprotectant in the management of dry eye disease.
    Morya AK; Solanki K; Prakash S; Samota M; Gupta A
    Taiwan J Ophthalmol; 2021; 11(2):161-167. PubMed ID: 34295622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of 0.3% carbomer gel compared to placebo in patients with moderate-to-severe dry eye syndrome.
    Sullivan LJ; McCurrach F; Lee S; Taylor HR; Rolando M; Marechal-Courtois C; Creuzot-Garcher C; Easty DL; Karabatsas C; Bingh Hoh M; Faschinger C; Laroche L
    Ophthalmology; 1997 Sep; 104(9):1402-8. PubMed ID: 9307633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of a fixed combination of 0.09 % xanthan gum/0.1 % chondroitin sulfate preservative free vs polyethylene glycol/propylene glycol in subjects with dry eye disease: a multicenter randomized controlled trial.
    Pérez-Balbuena AL; Ochoa-Tabares JC; Belalcazar-Rey S; Urzúa-Salinas C; Saucedo-Rodríguez LR; Velasco-Ramos R; Suárez-Sánchez RG; Rodríguez-Carrizalez AD; Oregón-Miranda AA
    BMC Ophthalmol; 2016 Sep; 16(1):164. PubMed ID: 27645318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy and safety of two eye gels in the treatment of dry eyes: Lacrinorm and Viscotears.
    Bron AJ; Daubas P; Siou-Mermet R; Trinquand C
    Eye (Lond); 1998; 12 ( Pt 5)():839-47. PubMed ID: 10070521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Multi-Ingredient Supplement Reduces Inflammation of the Eye and Improves Production and Quality of Tears in Humans.
    Radkar P; Lakshmanan PS; Mary JJ; Chaudhary S; Durairaj SK
    Ophthalmol Ther; 2021 Sep; 10(3):581-599. PubMed ID: 34129210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.